FDA Panel Backs Looser Limits On GSK's Avandia
A U.S. Food and Drug Administration panel on Thursday recommended dialing back restrictions on GlaxoSmithKline PLC's diabetes medicine Avandia after finding the risk of heart attacks had likely been overblown, but...To view the full article, register now.
Already a subscriber? Click here to view full article